57 results about "Hypoglycemic Effects" patented technology

The invention discloses a hexapeptide with a hypoglycemic effect as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the hexapeptide is Ile-Trp-Asp-Pro-His-Phe, and the amino acid sequence of the hexapeptide is as shown in the specification. The novel hexapeptide IWDPHF with prominent DPP-IV inhibition ability is successfully identified from mulberry leaf proteolysis products through liquid chromatography-mass spectrometry and a virtual screening method, the hexapeptide IWDPHF shows the blood glucose reducing effect superior to that of part of known peptides in an in-vitro enzyme activity inhibition experiment and a zebra fish hyperglycemia model, and no obvious side effect exists; the compound has a good potential of being developed into a hypoglycemic functional product or a drug lead compound. The invention further provides the mulberry leaf peptide with the peptide fragment IWDPHF, and the mulberry leaf peptide can be applied to preparation of drugs or food for reducing blood sugar. The invention provides a new scheme and theoretical basis for treatment of diabetes, and has good market prospect and application potential.

The technical scheme of the invention discloses black fungus protein capable of reducing blood glucose and resisting oxidation as well as a preparation method and application of the black fungus protein. The amino acid sequence of the black fungus protein is as shown in SEQ ID NO. 1. The protein which is separated and identified from the black fungus for the first time and has the effects of reducing blood glucose and resisting oxidation achieves the effect of reducing blood glucose through double inhibition of alpha-amylase and alpha-glucosidase, meanwhile, the protein has remarkable antioxidant activity, animal experiments prove that fasting blood glucose and body weight of a type II diabetes model mouse can be effectively reduced, and the protein has a good application prospect. The compound has high biological activity and safety, and can be used for developing functional products with hypoglycemic and antioxidant activity.

The invention relates to a sugar-free lung-moistening composition for treating diabetes mellitus yin deficiency and dry cough as well as application and a preparation method of the sugar-free lung-moistening composition, aiming at solving the problem that the existing cough-relieving traditional Chinese medicine products are generally not suitable for diabetics to use, and the sugar-free lung-moistening traditional Chinese medicine composition for treating diabetes mellitus yin deficiency and dry cough is prepared from the following raw materials in parts by weight. Comprising 30-40 parts of pears, 15-20 parts of radix polygonati officinalis, 10-15 parts of radix adenophorae, 10-15 parts of radix ophiopogonis, 5-10 parts of Chinese yam, 5-8 parts of fructus momordicae and 3-5 parts of fructus lycii. The sugar-free lung-moistening composition for diabetic yin deficiency and dry cough breaks through the limitation of single effect of a traditional medicine and food homology formula, and has the effects of relieving cough, eliminating phlegm, moistening lung, nourishing yin and assisting in reducing blood sugar.

To provide an adjuvant that can maintain the therapeutic effect while reducing the dose of the SU drugs since sulfonylurea drugs (hereinafter also referred to as "SU drugs"'), which are antidiabetic drugs, induce pancreatic β cell exhaustion when used long-term in addition to the side effects of hypoglycemia and weight gain and have side effects of reduced efficacy (hypoglycemic effect) and renal damage.SOLUTION: If D-allulose is administered before or simultaneously with SU drug administration, the hypoglycemic effect of SU drugs will be enhanced. As a result, the above-mentioned problem is solved because the dose of SU drugs can be significantly reduced. Furthermore, since D-allulose has been eaten by humans, it can provide a highly safe drug when combined with SU drugs.SELECTED DRAWING: Figure 3

According to the salivation promoting beverage for treating diabetes and the preparation method and chemical and pharmacokinetic application of the salivation promoting beverage, eight medicinal and edible medicinal materials such as folium mori and radix rehmanniae are scientifically matched, and a material basis is laid for the blood glucose reducing effect of a compound through the design of a multi-component and multi-target synergistic effect. The absorption, distribution, metabolism and excretion processes of active ingredients in traditional Chinese medicinal materials in a living body can be systematically illuminated through pharmacokinetic research, meanwhile, strict methodology verification is carried out, a UHPLC-Q-TOF-MS high-resolution mass spectrometry technology and a modern pharmacokinetic application method are creatively integrated, and a set of systematic traditional Chinese medicine compound application strategy is constructed. Not only is the hypoglycemic action mechanism of the compound clarified, but also an innovative technical path and a reliable application normal form are provided for modern application of the traditional Chinese medicine compound, and organic combination of chemical characterization and efficacy evaluation is realized.

This invention belongs to the technical field of pharmaceuticals, health foods, and medicines, specifically relating to Russula polysaccharide, its extraction method, and its application in anti-inflammatory, antioxidant, and / or hypoglycemic effects. This invention employs an ultrasound-assisted enzymatic hydrolysis method to extract Russula polysaccharide, thereby significantly improving extraction efficiency, reducing enzyme dosage, protecting the polysaccharide structure, and increasing yield and purity. Furthermore, experimental verification shows that it possesses good anti-inflammatory, antioxidant, and / or hypoglycemic effects, and when combined with Phyllanthus emblica polysaccharide, it synergistically enhances hypoglycemic performance, thus demonstrating significant practical application value.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The application discloses a quinoa hexapeptide with a blood sugar lowering effect and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the quinoa hexapeptide PGSPGR is Pro-Gly-Ser-Pro-Gly-Arg. The quinoa hexapeptide PGSPGR has alpha-glucosidase inhibitory activity and can effectively reduce blood sugar level, and therefore, can be applied to preparation of medicines or food for lowering blood sugar. The application further provides a polypeptide containing the peptide segment PGSPGR and a quinoa peptide rich in the polypeptide, and the polypeptide and the quinoa peptide are applied to preparation of medicines or food for lowering blood sugar, thereby providing a new scheme and theoretical basis for treatment of diabetes, and having good market prospect and application potential.

The invention belongs to the technical field of traditional Chinese medicine, and relates to polygonum cuspidatum homogeneous polysaccharide and a preparation method and application thereof.The polygonum cuspidatum homogeneous polysaccharide is mainly composed of galacturonic acid, rhamnose, galactose, glucuronic acid, glucose, mannose, xylose and glucuronide amine according to the molar ratio of 41.967: 24.624: 17.951: 5.427: 4.59: 3.501: 1.236: 0.358, and the weight-average molecular weight of the polygonum cuspidatum homogeneous polysaccharide is 26.57 kDa. The polygonum cuspidatum homogeneous polysaccharide is fixed in component, high in yield, good in hypoglycemic effect and good in safety, and a basis is provided for development of innovative hypoglycemic drugs.

This invention provides a fermented extract of Rehmannia glutinosa, a composition thereof, its preparation method, and its application, belonging to the field of biomedical technology. This invention obtains fermented extracts of black tea and Rehmannia glutinosa by fermenting black tea and Rehmannia glutinosa with a single strain of *Aspergillus cristatus*. Experiments have verified that both extracts, used alone, have good inhibitory effects on dipeptidyl peptidase-4. Further, combining the two extracts and verifying through animal experiments, shows that they have good inhibitory activity against dipeptidyl peptidase-4 in the intestine and feces, while also exhibiting a hypoglycemic effect.

The invention discloses a fish-derived active peptide with antioxidant and hypoglycemic effects, a preparation and application, and belongs to the technical field of biological active peptides. The fish-derived active peptide with the effects of resisting oxidation and reducing blood sugar is at least one of peptide fragments with amino acid sequences as shown in SEQ ID NO: 1-SEQ ID NO: 3. According to the invention, three active peptides with antioxidant and hypoglycemic effects are extracted from salmon by-products by adopting protease enzymolysis, LC-MS / MS, a bioinformatics method and other methods, and the active peptides have high DPPH clearance rate, ABTS free radical clearance rate and alpha-glucosidase and alpha-amylase inhibition rate. Therefore, the compound has an important application prospect in the development of products with the effects of resisting oxidation and reducing blood sugar.

The preparation method comprises the following steps: dissolving antioxidant dextrin and ferulic acid in deionized water to form a mixed solution, adjusting the pH value, adding transglucosidase, carrying out a reaction, carrying out enzyme deactivation, and carrying out freeze drying to obtain hydrophobic modified resistant dextrin; respectively dissolving the obtained hydrophobic modified resistant dextrin and thaumatin in a citric acid-sodium citrate buffer solution to form mother liquor, respectively adjusting the pH of the mother liquor, adding NaCl to adjust proper ionic strength, and slowly mixing the two blended mother liquor under magnetic stirring; after mixing, allowing the solution to stand at room temperature; according to the invention, unique characteristics of thaumatin and resistant dextrin are creatively and synergistically utilized, and a dual blood glucose reducing mechanism combining front-end resistance control and rear-end regulation is formed.

The invention belongs to the technical field of plant peptide preparation, and particularly relates to a preparation method of pea oligopeptide and application of the pea oligopeptide in the aspect of reducing blood sugar. The pea oligopeptide is prepared by taking pea protein as a raw material through an enzymolysis method, core peptide fragments VA, FPW and WPF of the pea oligopeptide are obtained through further identification on the basis, and VA, FPW and WPF are screened and confirmed as potential inhibitory peptides targeting DPP-IV by combining molecular docking and molecular dynamics simulation technologies. Besides, the DPP-IV inhibition rate of the core peptide fragment is further determined through an in-vitro experiment, and the FPW and the WPF are confirmed to be the core peptide fragment with efficient DPP-IV inhibition potential and have relatively good structural stability by combining cell experiment analysis, so that theoretical support is provided for the hypoglycemic effect of the pea peptide core peptide fragment, and a foundation is laid for development of hypoglycemic nutritional and healthy products.

The invention discloses quinoa hexapeptide with a hypoglycemic effect and application of the quinoa hexapeptide, and belongs to the technical field of bioactive peptides. The amino acid sequence of the chenopodium quinoa willd hexapeptide PGSPGR is Pro-Gly-Ser-Pro-Gly-Arg, and the chenopodium quinoa willd hexapeptide PGSPGR has alpha-glucosidase inhibitory activity and can effectively reduce the blood sugar level, so that the chenopodium quinoa willd hexapeptide PGSPGR can be applied to preparation of drugs or food for reducing blood sugar. The invention also provides a polypeptide containing the peptide fragment PGSPGR and a quinoa peptide rich in the polypeptide, which are applied to preparation of drugs or food for reducing blood sugar, provide a new scheme and theoretical basis for treatment of diabetes, and have good market prospects and application potential.

The invention relates to the technical field of biological medicines, in particular to saponin compounds separated from quinoa husks, and the compounds have remarkable lipid-lowering and blood-glucose-lowering effects, can effectively inhibit the expression of adipogenesis related proteins (such as FAS, ACC and SCD-1), and reduce the levels of triglyceride (TG), total cholesterol (TC) and glucose in cells.

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

This invention provides *Pediococcus lactis* SHI03 and its application in alleviating insulin resistance and type 2 diabetes, belonging to the field of microbial technology. This invention provides *Pediococcus lactis* SHI03, with accession number CCTCC No: M 20242686, and confirms that this strain possesses in vitro α-glucosidase inhibitory activity, exhibiting excellent probiotic and hypoglycemic effects. This invention further provides microbial products containing *Pediococcus lactis* SHI03, including *Pediococcus lactis* SHI03 fermentation broth, *Pediococcus lactis* SHI03 fermentation supernatant, and *Pediococcus lactis* SHI03 cells, and their applications in alleviating high-fat diet-induced insulin resistance and reducing fasting blood glucose in type 2 diabetic mice.

This invention relates to the field of biomedical technology, and more particularly to a *Lactobacillus paracasei* strain with significant hypoglycemic effects. This invention develops an engineered bacterium that continuously secretes a mutant GLP-1 protein, capable of expressing a fusion peptide containing a signal peptide, an enhancing peptide, and the mutant GLP-1 protein. It exhibits good passage stability and can exert a dual therapeutic effect on type 2 diabetes through continuous secretion of the mutant GLP-1 protein and regulation of the gut microbiota. The engineered bacterium of this invention can be used to prepare oral pharmaceutical formulations. Therefore, this invention provides a new technical means for developing non-invasive, cost-effective, and efficient drug delivery strategies targeting GLP-1, and has broad application prospects.

The invention relates to the technical field of food processing, and particularly discloses fermented broccoli powder with a hypoglycemic effect and a preparation method of the fermented broccoli powder. The method comprises the following steps: mixing broccoli corolla with sterilized water, pulping, inoculating broccoli endogenous lactobacillus plantarum Broc-Lp1 (CGMCC NO.24760), fermenting at 37 DEG C for 24 hours, pre-cooling, carrying out vacuum freeze drying, crushing and sieving to obtain the fermented broccoli powder. According to the method, the content of total phenols in broccoli is remarkably increased, and the inhibitory activity of broccoli on alpha-glucosidase is enhanced. The obtained product can be used for preparing a natural food additive with the functions of reducing blood sugar and losing weight, is safe and effective, and is suitable for daily diet application.

This invention discloses the application of chestnut total burdock ethanol extract in the preparation of hypoglycemic drugs. In this invention, the chestnut total burdock ethanol extract with hypoglycemic effect is obtained by reflux extraction of chestnut total burdock with 70% ethanol. This extract can significantly inhibit the activity of α-glucosidase and has a significant inhibitory effect on postprandial blood glucose levels in T2DM model mice, exhibiting a significant hypoglycemic effect in vivo.

The invention discloses a Lactobacillus paracasei G15 and an application thereof in food with an auxiliary blood glucose reducing effect. The lactobacillus paracasei G15 is classified and named as lactobacillus paracasei, the preservation number is CCTCC (China Center for Type Culture Collection) NO: M 20232497, the preservation unit is China Center for Type Culture Collection, and the preservation date is December 7, 2023. The lactobacillus paracasei G15 is used for generating organic acid and active peptide through metabolism, improving the fermentation characteristic of dough, and meanwhile achieving the synergistic hypoglycemic effect by adjusting intestinal flora and enhancing insulin sensitivity. The lactobacillus paracasei G15 can also cooperate with Gansu yeast to construct a composite fermentation system, food functions are improved through microbial metabolism conversion, antinutritional factors in food raw materials are decomposed, active peptides are released, short-chain fatty acids are generated, the starch digestion rate is further delayed, and rapid release of glucose is reduced.

This invention provides a method for preparing a metformin compound hypoglycemic oral solution, relating to the pharmaceutical field, comprising: step S1, pretreatment of traditional Chinese medicine components; step S2, enzymatic hydrolysis of the first group of traditional Chinese medicine components; step S3, supercritical extraction; step S4, preparation of mixed traditional Chinese medicines; step S5, preparation of inclusion complex; step S6, compound formulation; and step S7, post-processing. This method synergistically combines extracts from seven traditional Chinese medicines—bitter melon, phellodendron bark, astragalus root, kudzu root, rehmannia root, ginseng, and privet fruit—with metformin hydrochloride to form a metformin compound hypoglycemic oral solution, balancing the synergy, safety, and stability of traditional Chinese and Western medicines, thereby improving hypoglycemic effects while reducing the incidence of gastrointestinal adverse reactions to metformin.

The present application provides a Morchella source hypoglycemic peptide and application thereof, and belongs to the technical field of biological medicine. The present application provides a Morchella source hypoglycemic peptide, which comprises a tripeptide and / or a tetrapeptide; the amino acid sequence of the tripeptide is PTW, and the amino acid sequence of the tetrapeptide is MPTW. The Morchella source hypoglycemic peptide of the present application has a molecular weight less than 1000, strong hydrophobicity, and contains Pro and Trp. Molecular docking results show that PTW and / or MPTW can be combined with the proteinase diabetes prevention and treatment target dipeptidyl peptidase IV, protein tyrosine phosphatase 1B and alpha-amylase to play a hypoglycemic role through hydrogen bonding and hydrophobic interaction. Moreover, the hypoglycemic peptide of the present application is a natural product, has no hemolyticity and allergenicity, and has good pharmacokinetic characteristics. The present application has certain guiding significance for the development of food source hypoglycemic peptides.

The application discloses a walnut source DPP-IV inhibiting peptide as well as a preparation, identification and screening method and application thereof, and belongs to the technical field of biological medicines. A series of novel DPP-IV inhibiting peptides, KFPF, IFR, KGFL, KIPF and KLF, are screened and verified from walnut proteins in a high efficiency for the first time. Not only is the rational discovery of high-activity peptides realized through a systematic method of'multi-frequency ultrasonic pretreatment-enzymolysis-ultrafiltration purification-mass spectrometric identification-computer virtual screening-in vitro and in vivo activity verification', but also the clear hypoglycemic effect of the peptides is confirmed in animal experiments. The application provides new candidate molecules for developing natural and safe anti-diabetic functional foods or medicines, and has good industrial value and scientific significance through improving the added value of walnut resources and establishing a replicable active peptide research paradigm.

The invention discloses a novel BimBH3 mimic peptide analogue constructed on the basis of a nailing and fatty acid acylation dual-modification strategy and application of the novel BimBH3 mimic peptide analogue serving as a PTPN1 inhibitor to development of a long-acting hypoglycemic drug. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The structural general formula of the BimBH3 mimic peptide analogue is as shown in a formula I. The invention provides the BimBH3 mimic peptide analogue with a novel structure, and the BimBH3 mimic peptide analogue is constructed by adopting a nailing and fatty acid acylation dual-modification strategy and has the structural general formula as shown in the formula I. The invention further provides a preparation method of the BimBH3 mimic peptide analogue. On the basis of a BimBH3 functional domain core sequence, the novel BimBH3 mimic peptide analogue has target inhibitory activity, metabolic stability and in-vivo action durability through second-site lysine substitution, N-terminal palmitic acid conjugation and fifth, sixth and ninth site glutamic acid side chain mediated synthesis ring nailing modification, and the synthesis ring nailing mode is molecular lactam cyclization. Experiments show that the compound can efficiently inhibit PTPN1 activity, has a long-acting hypoglycemic effect in a type 2 diabetes animal model, and has the potential of being developed into a long-acting antidiabetic drug which is administered once a week. The invention also discloses a solid-phase synthesis preparation method of the compound and application of the compound as a potential PTPN1 inhibitor drug.

This invention belongs to the field of biotechnology, specifically relating to an α-glucosidase inhibitory peptide and its applications. The invention uses oat bran as raw material to extract protein, prepares oat bioactive peptides through enzymatic hydrolysis, and uses bioinformatics analysis to screen for the α-glucosidase inhibitory peptide RELGGFF, which exhibits an IC50 value of 531.90±5.23 μg / mL against α-glucosidase. Furthermore, the inhibitory effect of the combined use of the α-glucosidase inhibitory peptide RELGGFF and oat β-glucan on α-glucosidase activity is investigated, and its application can be explored in the preparation of products that inhibit α-glucosidase activity, in the preparation of hypoglycemic products, or in the preparation of products for treating diabetes.

The invention relates to the field of medicines, and particularly discloses application of dapagliflozin to preparation of a medicine for preventing and / or treating obesity-related salt-sensitive hypertension. According to the application, the new application of dapagliflozin in prevention and treatment of a specific and high-risk disease subtype of obesity-related salt-sensitive hypertension is defined for the first time. Experiments prove that dapagliflozin can improve the sodium treatment function of the kidney and promote urine sodium excretion by inhibiting abnormal continuous coupling of a Na / K-ATPase / c-Src signal axis in the kidney. The discovery reveals a new kidney protection mechanism of dapagliflozin independent of the hypoglycemic effect, and provides a new drug use and a treatment scheme for clinical prevention and treatment of obesity-related renal sodium metabolism disorders and salt-sensitive hypertension.

The invention belongs to the field of pharmaceutical preparations, and particularly discloses a mulberry leaf flavone microcapsule with a hypoglycemic effect as well as a preparation method and application thereof, and the mulberry leaf flavone microcapsule is prepared from the following raw and auxiliary materials in parts by weight: 3 parts of mulberry leaf flavone, 5-12 parts of chickpea modified protein, 2-8 parts of sodium alginate, 9-13 parts of calcium chloride and 14-18 parts of glutamine transaminase. The chickpea modified protein and the sodium alginate are used as composite wall materials, mulberry leaf flavone is embedded under auxiliary crosslinking of calcium chloride and glutamine transaminase, and the prepared mulberry leaf flavone microcapsule is small in particle size, high in encapsulation efficiency and good in mechanical stability, has the intestinal targeted slow release characteristic and can be used for preparing the mulberry leaf flavone microcapsule. The in-vivo bioavailability of the mulberry leaf flavone is obviously improved, the effect of treating diabetes mellitus is more excellent, and the practical popularization and application value is achieved.